Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin b in the treatment of fungal infections in cancer patients: A review
- 1 January 1999
- journal article
- review article
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 3 (2) , 109-118
- https://doi.org/10.1016/s1201-9712(99)90019-x
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Candidemia in Cancer Patients: A Prospective, Multicenter Surveillance Study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)Clinical Infectious Diseases, 1999
- Antifungal treatment in patients with cancerJournal of Internal Medicine, 1997
- Trends in the postmortem epidemiology of invasive fungal infections at a University HospitalJournal of Infection, 1996
- The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistanceThe American Journal of Medicine, 1996
- Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytopenic cancer patients: a pragmatic, multicentre, prospective and randomised clinical trialEuropean Journal Of Cancer, 1996
- Importance of Candida Species Other than C. albicans as Pathogens in Oncology PatientsClinical Infectious Diseases, 1995
- Editorial Response: Evolving Risk Factors for Invasive Fungal Infections--All Neutropenic Patients Are Not the SameClinical Infectious Diseases, 1994
- Changes in the Spectrum of Fungal Infections in Bone Marrow Transplant PatientsInfectious Diseases in Clinical Practice, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- The Spectrum of Non-Candida Fungal Infections following Bone Marrow TransplantationMedicine, 1993